Last reviewed · How we verify
NCT05497843
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
Completed
Phase 2
Last updated 3 April 2025
What this trial tests
Phase 2 trial testing Chiauranib in Soft Tissue Sarcoma in 40 participants. Completed in 3 January 2025.
Timeline
25 August 2022
Primary endpoint
3 January 2025
3 January 2025
3 January 2025
Quick facts
| Lead sponsor | Chipscreen Biosciences, Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 25 August 2022 |
| Primary completion | 3 January 2025 |
| Estimated completion | 3 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chiauranib — full drug profile →
Conditions studied
- Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →
Sponsor
Chipscreen Biosciences, Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z -
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010 -
Aurora kinases signaling in cancer: from molecular perception to targeted therapies.
Vats P, Saini C, Baweja B, Srivastava SK, et al · · 2025 · cited 6× · PMID 40533769 · DOI 10.1186/s12943-025-02353-3 -
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities.
Liu H, Wang X, Liu L, Yan B, et al · · 2024 · cited 2× · PMID 39723387 · DOI 10.3389/fonc.2024.1484027 -
MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.
Al Jarroudi O, El Bairi K, Brahmi SA, Afqir S. · · 2025 · PMID 40909947 · DOI 10.3389/fonc.2025.1418537
Verify or expand the search:
- PubMed search for NCT05497843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chiauranib
Trials testing the same drug.
- NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
- NCT06492915 — Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma · Phase 2 · active not recruiting
- NCT05371899 — Mass Balance Study of [14C]Chiauranib · NA · completed
- NCT05346601 — Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers · Phase 1 · completed
- NCT05336721 — A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC · Phase 2 · terminated
Other recruiting trials for Soft Tissue Sarcoma
Currently open trials in the same condition.
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
- NCT07243626 — Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07049848 — SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radi · Phase 2 · recruiting
- NCT06962072 — Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma · recruiting
- NCT06905132 — Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma · Phase 2 · recruiting
Other Chipscreen Biosciences, Ltd. trials
Trials by the same sponsor.
- NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
- NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
- NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
- NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05497843 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05497843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing